Validating bifidobacterial species and subspecies identity in commercial probiotic products

Pediatric Research

Volumn 79, Issue 3, 2016, Pages 445-452

  Lewis, Zachery T ^a   Shani, Guy ^a   Masarweh, Chad F ^a   Popovic, Mina ^b   Frese, Steve A ^a   Sela, David A ^c   Underwood, Mark A ^a,d   Mills, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; PROBIOTIC AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENOME; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM INFANTIS; BIFIDOBACTERIUM LONGUM; CONTROLLED STUDY; DNA POLYMORPHISM; GENOME SIZE; METABOLIC CAPACITY; MICROBIAL COMMUNITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ALIGNMENT; SUBSPECIES; VALIDATION PROCESS; BACTERIUM IDENTIFICATION; CLASSIFICATION; DNA SEQUENCE; ENTEROCOLITIS, NECROTIZING; FECES; GENETICS; HUMAN; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIOLOGY; NEWBORN; PREMATURITY; SPECIES DIFFERENCE; VALIDATION STUDY;

BACTERIAL TYPING TECHNIQUES; BIFIDOBACTERIUM; DNA, BACTERIAL; ENTEROCOLITIS, NECROTIZING; FECES; GENOME, BACTERIAL; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROBIOTICS; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84962720399     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2015.244     Document Type: Article

References (41)

1. Fasoli S, Marzotto M, Rizzotti L, Rossi F, Dellaglio F, Torriani S. Bacterial composition of commercial probiotic products as evaluated by PCRDGGE analysis. Int J Food Microbiol 2003; 82: 59-70
2. Canganella F, Paganini S, Ovidi M, et al. A microbiology investigation on probiotic pharmaceutical products used for human health. Microbiol Res 1997; 152: 171-9
3. Angelakis E, Million M, Henry M, Raoult D. Rapid and accurate bacterial identification in probiotics and yoghurts by MALDI-TOF mass spectrometry. J Food Sci 2011; 76: M568-72
4. Goldstein EJ, Citron DM, Claros MC, Tyrrell KL. Bacterial counts from five over-The-counter probiotics: are you getting what you paid for? Anaerobe 2014; 25: 1-4
5. Marcobal A, Underwood MA, Mills DA. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr 2008; 46: 608-11
6. Patro JN, Ramachandran P, Lewis JL, et al. Development and utility of the FDA ?GutProbe? DNA microarray for identification, genotyping and metagenomic analysis of commercially available probiotics. J Appl Microbiol 2015; 118: 1478-88
7. Temmerman R, Pot B, Huys G, Swings J. Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int J Food Microbiol 2003; 81: 1-10
8. Huys G, Vancanneyt M, D?Haene K, Vankerckhoven V, Goossens H, Swings J. Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res Microbiol 2006; 157: 803-10
9. Madan JC, Farzan SF, Hibberd PL, Karagas MR. Normal neonatal microbiome variation in relation to environmental factors, infection and allergy. Curr Opin Pediatr 2012; 24: 753-9
10. Zivkovic AM, Lewis ZT, German JB, Mills DA. Establishment of a Milk-Oriented Microbiota (MOM) in early life: How Babies Meet Their MOMs. Funct Food Rev 2013; 5: 3-12
11. La Rosa PS, Warner BB, Zhou Y, et al. Patterned progression of bacterial populations in the premature infant gut. Proc Natl Acad Sci USA 2014; 111: 12522-7
12. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health 2014; 9: 584-671
13. Bokulich NA, Mills DA, Underwood MA. Surface microbes in the neonatal intensive care unit: changes with routine cleaning and over time. J Clin Microbiol 2013; 51: 2617-24
14. Brooks B, Firek BA, Miller CS, et al. Microbes in the neonatal intensive care unit resemble those found in the gut of premature infants. Microbiome 2014; 2: 1
15. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr 2010; 156: 679-81
16. Jenke A, Ruf EM, Hoppe T, Heldmann M, Wirth S. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child Fetal Neonatal Ed 2012; 97: F217-8
17. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-7
18. Turroni F, Peano C, Pass DA, et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 2012; 7: e36957
19. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543-7
20. Huda MN, Lewis Z, Kalanetra KM, et al. Stool microbiota and vaccine responses of infants. Pediatrics 2014; 134: e362-72
21. Romond MB, Colavizza M, Mullie C, et al. Does the intestinal bifidobacterial colonisation affect bacterial translocation? Anaerobe 2008; 14: 43-8
22. Chichlowski M, De Lartigue G, German JB, Raybould HE, Mills DA. Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. J Pediatr Gastroenterol Nutr 2012; 55: 321-7
23. Sheil B, MacSharry J, O?Callaghan L, et al. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-Type and IL-10 knock-out mice. Clin Exp Immunol 2006; 144: 273-80
24. Tanabe S, Kinuta Y, Saito Y. Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. Int J Mol Med 2008; 22: 181-5
25. Preising J, Philippe D, Gleinser M, et al. Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. Appl Environ Microbiol 2010; 76: 3048-51
26. Underwood MA, Kalanetra KM, Bokulich NA, et al. A comparison of two probiotic strains of bifidobacteria in premature infants. J Pediatr 2013; 163: 1585-1591.e9
27. Sela DA, Chapman J, Adeuya A, et al. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci USA 2008; 105: 18964-9
28. LoCascio RG, Ninonuevo MR, Freeman SL, et al. Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. J Agric Food Chem 2007; 55: 8914-9
29. LoCascio RG, Desai P, Sela DA, Weimer B, Mills DA. Broad conservation of milk utilization genes in Bifidobacterium longum subsp. infantis as revealed by comparative genomic hybridization. Appl Environ Microbiol 2010; 76: 7373-81
30. Garrido D, Kim JH, German JB, Raybould HE, Mills DA. Oligosaccharide binding proteins from Bifidobacterium longum subsp. infantis reveal a preference for host glycans. PLoS One 2011; 6: e17315
31. Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol 2013; 304: G132-41
32. Schell MA, Karmirantzou M, Snel B, et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci USA 2002; 99: 14422-7
33. Lewis ZT, Bokulich NA, Kalanetra KM, Ruiz-Moyano S, Underwood MA, Mills DA. Use of bifidobacterial specific terminal restriction fragment length polymorphisms to complement next generation sequence profiling of infant gut communities. Anaerobe 2013; 19: 62-9
34. Ewaschuk JB, Diaz H, Meddings L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1025-34
35. Mattareli P, Bonaparte C, Pot B, et al. Proposal to reclassify the three biotypes of Bifidobacterium longum as three subspecies: Bifidobacterium longum subsp. longum subsp. nov., Bifidobacterium longum subsp. infantis comb. nov. and Bifidobacterium longum subsp. suis comb. nov. Int J Syst Evol Microbiol 2008; 58: 767-772
36. Lewis ZT, Totten SM, Smilowitz JT, et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 2015; 3: 13
37. Lee JH, Karamychev VN, Kozyavkin SA, et al. Comparative genomic analysis of the gut bacterium Bifidobacterium longum reveals loci susceptible to deletion during pure culture growth. BMC Genomics 2008; 9: 247
38. Ofek Shlomai N, Deshpande G, Rao S, Patole S. Probiotics for preterm neonates: what will it take to change clinical practice? Neonatology 2014; 105: 64-70
39. Janvier A, Malo J, Barrington KJ. Cohort study of probiotics in a North American neonatal intensive care unit. J Pediatr 2014; 164: 980-5
40. Donovan SM. Promoting bifidobacteria in the human infant intestine: why, how, and which one? J Pediatr Gastroenterol Nutr 2011; 52: 648-9
41. Ruiz-Moyano S, Totten SM, Garrido DA, et al. Variation in consumption of human milk oligosaccharides by infant gut-Associated strains of Bifidobacterium breve. Appl Environ Microbiol 2013; 79: 6040-9